8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): September 9, 2004


                               NuWay Medical, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


              Delaware                 000-19709           65-0159115
   (State or other jurisdiction      (Commission         (IRS Employer
         of incorporation)           File Number)      Identification No.)


           23461 South Pointe Drive, Suite 200, Laguna Hills, CA 92653
           -------------------------------------------------------------
               (Address of principal executive offices)       (Zip Code)


       Registrant's telephone number, including area code: (949) 454-9011


                                 Not Applicable
         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ]   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

[ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

[ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17CFR 240.14d-2(b))

[ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17CFR 240.13e-4(c))




ITEM 4.01   CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT

         After continuing discussions between NuWay Medical, Inc. (the
"Company") and Haskell & White LLP ("H&W"), concerning the financial terms of
re-engagement as the Company's auditors for the fiscal year ended December 31,
2003, the Company and H&W mutually agreed to terminate the engagement of H&W on
September 9, 2004. H&W had initially been engaged by the Company on March 31,
2003. The decision to change accountants was recommended by the Audit Committee
of the Company's Board of Directors.

      The Company has begun actively to look for new auditors and intends to
retain new auditors as soon as the Company can arrange adequate financing to
engage the new auditors and, thereafter, as reasonably practicable as possible,
to file all outstanding reports under the Securities Exchange Act of 1934, as
amended. The Company has authorized H&W to respond fully to successor auditor
inquiries.

      H&W's report, dated May 12, 2003, on the consolidated financial statements
as of and for the year ended December 31, 2002, contained no adverse opinion or
disclaimer of opinion, nor was modified as to uncertainty, audit scope, or
accounting principles. However, H&W's report included an explanatory paragraph
noting the Company's limited liquid resources, recurring losses from operations
and the Company's efforts to implement its business plan with a new industry
focus, all of which raised substantial doubt about the Company's ability to
continue as a going concern.

      During the Company's relationship with H&W, since H&W's initial engagement
as the principal auditors on March 31, 2003, through August 9, 2004, there were
no disagreements with H&W, whether or not resolved, on any matter of accounting
principles or practices, financial statement disclosure, or auditing scope or
procedure, which, if not resolved to H&W's satisfaction, would have caused it to
make reference to the subject matter of the disagreement(s) in connection with
its report on the consolidated financial statements for the year ended December
31, 2002.

      The Company has provided to H&W a copy of this disclosure and has
requested H&W to furnish the Company with a letter addressed to the Securities
and Exchange Commission stating whether H&W agrees with the statements made by
the Company in this report. H&W's letter is attached hereto as Exhibit 16.1.

ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS

Exhibit
Number            Description
- -------           -----------

16.1              Letter from Haskell & White LLP to the Securities and Exchange
                  Commission dated September 10, 2004.




                                   SIGNATURES


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  September 10, 2004                         NUWAY MEDICAL, INC.

                                                  By:  /s/ Dennis Calvert
                                                  ----------------------------
                                                  Dennis Calvert
                                                  Chief Executive Officer

EX-16.1

                                                                    EXHIBIT 16.1


Securities and Exchange Commission
450 5th Street, N.W.
Washington, D.C.  20549


Ladies and Gentlemen:

         We have read NuWay Medical, Inc.'s statements included under Item 4.01
of its Current Report on Form 8-K dated September 9, 2004, and we agree with
such statements, except we are not in a position to agree or disagree with the
Company's statements made in the last sentence of the first paragraph and the
first sentence of the second paragraph under Item 4.01.



                                                    /s/ HASKELL & WHITE LLP

Irvine, California
September 10, 2004